The Food and Drug Administration (FDA or the Agency) is extending the comment period for the notice that appeared in the Federal Register of August 14, 2017. In the notice, FDA requested comments concerning abuse potential, actual abuse, medical usefulness, trafficking, and impact of scheduling changes on availability for medical use of 17 drug substances. The Agency is taking this action in response to requests for an extension to allow interested persons additional time to submit comments.
Document
International Drug Scheduling; Convention on Psychotropic Substances; Single Convention on Narcotic Drugs; Ocfentanil, Carfentanil, Pregabalin, Tramadol, Cannabidiol, Ketamine, and Eleven Other Substances; Extension of Comment Period
The Food and Drug Administration (FDA or the Agency) is extending the comment period for the notice that appeared in the Federal Register of August 14, 2017. In the notice, FDA ...
Legal Citation
Federal Register Citation
Use this for formal legal and research references to the published document.
82 FR 42818
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“International Drug Scheduling; Convention on Psychotropic Substances; Single Convention on Narcotic Drugs; Ocfentanil, Carfentanil, Pregabalin, Tramadol, Cannabidiol, Ketamine, and Eleven Other Substances; Extension of Comment Period,” thefederalregister.org (September 12, 2017), https://thefederalregister.org/documents/2017-19261/international-drug-scheduling-convention-on-psychotropic-substances-single-convention-on-narcotic-drugs-ocfentanil-carfe.